The Brown lab studies mechanisms determining endogenous antitumor T cell priming and function in malignant brain tumors and other tumor types. In doing so, the lab seeks to develop new and improved in situ vaccine strategies and paradigms that engender productive immune rejection of tumors. To this end, we decode molecular mechanisms by which virotherapy induces antitumor T cell immunity, define mechanisms that improve the antitumor efficacy of in situ vaccination, and identify and mechanistically explain clinical correlates of response to immunotherapy.